Moderna and Merck's mRNA Cancer Vaccine Succeeds in Phase 3

The news serves as a strong catalyst for Moderna, and the Phase 3 success could positively impact the stock. However, with the price surging 150% in the last 24 hours and the RSI at 83, indicating overbought conditions, a sharp short-term rally may be followed by profit-taking. While the MACD is positive and above the signal line, suggesting a strong trend, initiating new positions at these levels could be risky. Therefore, despite the upward direction, I expect limited upside or consolidation rather than a strong continuation rally. It would be healthier for investors to maintain current positions and wait for pullbacks for new entries.

Despite JST being in oversold territory with an RSI of 23, the MACD remains negative and below the signal line, indicating weak short-term momentum. The price is trading below both the SMA20 and SMA50, suggesting the downtrend may continue. The news is not directly related to the crypto market and has limited potential to affect overall risk appetite. Although technical indicators signal oversold conditions, there is no clear catalyst for a price recovery. Therefore, I believe the downward movement may persist in the short term, but the pace of decline could slow.

News indicates that Moderna and Merck's mRNA cancer vaccine has succeeded in Phase 3 trials, serving as a positive catalyst for MRK stock. Technical indicators are in overbought territory (RSI 86), and the price has risen 12% in 24 hours, suggesting that the upward momentum may continue in the short term but carries a risk of overheating. The MACD is positive and above the signal line, indicating strong momentum. However, after such a rapid rise, profit-taking or consolidation may occur in the near term. Nevertheless, given the strength of the news and trend support, an upward movement can be expected, though caution is advised.